Zahraa Chayed1, Lone Krøldrup Kristensen2, Lilian Bomme Ousager2, Karina Rønlund3, Anette Bygum4. 1. Department of Clinical Research, University of Southern Denmark, Odense, Denmark. zacha15@student.sdu.dk. 2. Department of Clinical Genetics, Odense University Hospital, Odense, Denmark. 3. Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark. 4. Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.
Abstract
BACKGROUND: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genodermatosis characterized by cutaneous leiomyoma (CLM), uterine leiomyoma (ULM) and renal cell carcinoma (RCC). Five HLRCC patients are presented with a compiled database of published HLRCC cases to increase understanding of HLRCC. Furthermore, a surveillance program is suggested. Our review is based on a PubMed search which retrieved case reports and cohort studies published before November 2019. The search yielded 97 original papers with a total of 672 HLRCC patients. RESULTS: CLMs were present in 474 patients (71.5%), developed at the mean age of 28 years. Five patients had cutaneous leiomyosarcomas. ULMs were present in 356 women (83%), while two had uterine leiomyosarcoma. ULMs were diagnosed at a mean age of 32 years, with the youngest diagnosed at age 17 years. The most common surgical treatment for ULMs was hysterectomy, performed at a mean age of 35 years, with the youngest patient being 19 years old. RCCs were present in 189 patients (34.9%), of which half had metastatic disease. The mean age of diagnosis was 36 years with the youngest patient diagnosed with RCC at the age of 11 years. CONCLUSION: We suggest a surveillance program for HLRCC including a dermatological examination once every 2 years, annual magnetic resonance imaging starting at the age of 10 years to monitor for early RCCs, annual gynecological examinations from the age of 15 years and counseling regarding risk of hysterectomy and family planning at the age of 18 years. CLMs are often the earliest manifestation of HLRCC, which is why recognizing these lesions, performing a biopsy, and making a prompt referral to genetic counseling is important in order to diagnose HLRCC early.
BACKGROUND:Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genodermatosis characterized by cutaneous leiomyoma (CLM), uterine leiomyoma (ULM) and renal cell carcinoma (RCC). Five HLRCC patients are presented with a compiled database of published HLRCC cases to increase understanding of HLRCC. Furthermore, a surveillance program is suggested. Our review is based on a PubMed search which retrieved case reports and cohort studies published before November 2019. The search yielded 97 original papers with a total of 672 HLRCC patients. RESULTS: CLMs were present in 474 patients (71.5%), developed at the mean age of 28 years. Five patients had cutaneous leiomyosarcomas. ULMs were present in 356 women (83%), while two had uterine leiomyosarcoma. ULMs were diagnosed at a mean age of 32 years, with the youngest diagnosed at age 17 years. The most common surgical treatment for ULMs was hysterectomy, performed at a mean age of 35 years, with the youngest patient being 19 years old. RCCs were present in 189 patients (34.9%), of which half had metastatic disease. The mean age of diagnosis was 36 years with the youngest patient diagnosed with RCC at the age of 11 years. CONCLUSION: We suggest a surveillance program for HLRCC including a dermatological examination once every 2 years, annual magnetic resonance imaging starting at the age of 10 years to monitor for early RCCs, annual gynecological examinations from the age of 15 years and counseling regarding risk of hysterectomy and family planning at the age of 18 years. CLMs are often the earliest manifestation of HLRCC, which is why recognizing these lesions, performing a biopsy, and making a prompt referral to genetic counseling is important in order to diagnose HLRCC early.
Entities:
Keywords:
HLRCC; Hereditary leiomyomatosis and renal cell carcinoma; Surveillance program
Authors: N Afrina Alam; Ella Barclay; Andrew J Rowan; Jonathan P Tyrer; Eduardo Calonje; Sanjiv Manek; David Kelsell; Irene Leigh; Simon Olpin; Ian P M Tomlinson Journal: Arch Dermatol Date: 2005-02
Authors: M-H Wei; O Toure; G M Glenn; M Pithukpakorn; L Neckers; C Stolle; P Choyke; R Grubb; L Middelton; M L Turner; M M Walther; M J Merino; B Zbar; W M Linehan; J R Toro Journal: J Med Genet Date: 2005-06-03 Impact factor: 6.318
Authors: Fred H Menko; Eamonn R Maher; Laura S Schmidt; Lindsay A Middelton; Kristiina Aittomäki; Ian Tomlinson; Stéphane Richard; W Marston Linehan Journal: Fam Cancer Date: 2014-12 Impact factor: 2.375
Authors: Pierre I Karakiewicz; Claudio Jeldres; Nazareno Suardi; George C Hutterer; Paul Perrotte; Umberto Capitanio; Vincenzo Ficarra; Luca Cindolo; Alexandre de La Taille; Jacques Tostain; Peter F Mulders; Laurent Salomon; Richard Zigeuner; Luigi Schips; Denis Chautard; Antoine Valeri; Eric Lechevallier; Jean-Luc Descots; Herve Lang; Arnaud Mejean; Gregory Verhoest; Jean-Jacques Patard Journal: Can Urol Assoc J Date: 2008-12 Impact factor: 1.862
Authors: Onchee Yu; Delia Scholes; Renate Schulze-Rath; Jane Grafton; Kelly Hansen; Susan D Reed Journal: Am J Obstet Gynecol Date: 2018-10-03 Impact factor: 8.661
Authors: Graeme R Clark; Marco Sciacovelli; Edoardo Gaude; Diana M Walsh; Gail Kirby; Michael A Simpson; Richard C Trembath; Jonathan N Berg; Emma R Woodward; Esther Kinning; Patrick J Morrison; Christian Frezza; Eamonn R Maher Journal: J Clin Endocrinol Metab Date: 2014-07-08 Impact factor: 5.958